Your Letters: April 26, 2021
Reader Submissions
Biden’s ‘Gong Show’
For those old enough to remember “The Gong Show” from the mid-1970s, that talent show for amateurs reminds me of the Biden administration. You can search old clips of the show on YouTube. I ask, does the current group in Washington appear related to some of the contestants? If you believe in prayer, you best start praying now.
Bob Craig, Apple Valley
Let the complaining begin
Let freedom ring! The annual bombardment of illegal explosions and fireworks will soon ring loud. The illegals are already stocking their ware(houses). We the public are getting our stress pills. Our pets must endure another season of panic, stress and fright. The authorities are dusting off their annual excuses.
CSUN Model UN Wins Outstanding Delegation at New York Conference csun.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from csun.edu Daily Mail and Mail on Sunday newspapers.
Conco Services LLC Achieves Zero Recordable Incidents Two Years Consecutively and Names New Safety Director
News provided by
Share this article
Share this article
PITTSBURGH, April 20, 2021 /PRNewswire/ Conco Services LLC, with its headquarters in Pittsburgh, PA, and offices in La Porte, TX, Gonzales, LA, and Antioch, CA, has achieved a Total Recordable Incident Rate of zero, two years in a row. In addition to this hard-earned success, Timothy Meyer of Lake Charles, LA has been named Conco s Safety Director.
Meyer has over 30 years of industry experience and currently oversees Conco s domestic Industrial Division. In his 11 years at Conco, all Industrial projects have been completed safely and without any OSHA recordables, and he was promoted to Vice President over Industrial Markets in 2016. Since Meyer s move to leadership, Conco has been nominated for Houston Business Roundtable s Safety Excellence Award four times, has been named a Small Environmental Finalist two
Share:
BELTSVILLE, Md., April 10, 2021 (GLOBE NEWSWIRE) NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today presented preclinical and investigational new drug (IND)-enabling data for NC762 at the American Association for Cancer Research (AACR) Annual Meeting 2021. NC762 is a humanized monoclonal antibody specific for B7-H4 and is being developed for the treatment of cancer. The research presented by our team reinforces our confidence that NC762, our third program, is a novel immunomedicine with unique anti-tumor properties. We believe it has the potential to provide benefit in multiple oncology indications, particularly in cancers where high B7-H4 expression has been observed, such as breast, ovarian and lung cancers, said Michael Richman, NextCure s president and chief executive officer. We look forward to advancing NC76
NextCure to Present at the 20th Annual Needham Virtual Healthcare Conference benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.